A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b ...

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...

Data support potential of innovative gene therapy using novel RNA editing, paired with targeted AAV.ai delivery and scalable ...

Ionis Pharmaceuticals IONS reported first-quarter 2025 adjusted loss of 75 cents per share, narrower than the Zacks Consensus ...

STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

This partnership marks an important milestone for Creyon as we work to advance our RNA-targeted oligo therapy pipeline to the clinic for both rare and common diseases,” said Serge Messerlian ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...